Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 8:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Phosphorus binder Clear all
Not listed Phase 3 Interventional

Study Comparing Effects of Lanthanum Carbonate Versus Calcium Acetate Versus Dietary Phosphorus Restriction

NCT01357317
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Diet counseling, Phosphorus binder
Other · Drug
Lead sponsor
Salem Veterans Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Salem, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 11, 2012 · Synced Sep 6, 2026, 8:15 AM EDT
Recruiting Phase 3 Interventional

A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis

NCT03633708
View directory record Official record
Conditions
Secondary Hyperparathyroidism, Chronic Kidney Disease
Interventions
Etelcalcetide, Standard of Care
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
0 Years to 18 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
10
States / cities
Los Angeles, California • Aurora, Colorado • Kansas City, Missouri + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 6, 2026, 8:15 AM EDT
Completed Phase 4 Interventional Results available

Transition to Ferric Citrate Among Hemodialysis and Peritoneal Dialysis Patients

NCT03079869
View directory record Official record
Conditions
Hyperphosphatemia
Interventions
Ferric Citrate
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
Not listed
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2022 · Synced Sep 6, 2026, 8:15 AM EDT
Recruiting Phase 3 Interventional

A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China

NCT06933472
View directory record Official record
Conditions
Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis, ESRD (End-Stage Renal Disease), Dialysis
Interventions
AP301, AP301 Low Dose
Drug
Lead sponsor
Alebund Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
18
States / cities
Granada Hills, California • San Dimas, California • Lone Tree, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Sep 6, 2026, 8:15 AM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia

NCT04549597
View directory record Official record
Conditions
Chronic Kidney Disease Requiring Chronic Dialysis, Hyperphosphatemia
Interventions
Tenapanor
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 90 Years
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Lauderdale Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Sep 6, 2026, 8:15 AM EDT
Completed Phase 4 Interventional Results available

Equivalence of Calcium Acetate Oral Solution and Sevelamer Carbonate Tablets in Hemodialysis Patients

NCT01427907
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Calcium acetate oral solution (COS), Sevelamer carbonate
Drug
Lead sponsor
Fresenius Medical Care North America
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
New Haven, Connecticut • North Haven, Connecticut • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Sep 6, 2026, 8:15 AM EDT
Completed Phase 3 Interventional Results available

A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis

NCT01191255
View directory record Official record
Conditions
Hyperphosphatemia, Kidney Failure
Interventions
ferric citrate, ca acetate, sevelamer carbonate, placebo
Drug
Lead sponsor
Keryx Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
52
States / cities
Tempe, Arizona • Los Angeles, California • Riverside, California + 45 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2014 · Synced Sep 6, 2026, 8:15 AM EDT
Completed Phase 4 Interventional Results available

Phosphate Lowering in CKD Trial

NCT02209636
View directory record Official record
Conditions
Chronic Kidney Disease, Cardiovascular Disease
Interventions
Lanthanum carbonate, placebo, Ascorbic Acid, Nitroglycerin, Flow-mediated dilation measurement, Aortic pulse-wave velocity, Endothelial cell collection
Drug · Procedure
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 79 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Sep 6, 2026, 8:15 AM EDT
Completed Not applicable Interventional

Phosphate Kinetic Modeling

NCT01003223
View directory record Official record
Conditions
End Stage Renal Disease, Hyperphosphatemia
Interventions
Computer algorithm management of hyperphosphatemia
Other
Lead sponsor
Fresenius Medical Care North America
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 17, 2014 · Synced Sep 6, 2026, 8:15 AM EDT
Completed Phase 2 Interventional Results available

A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD)

NCT00648167
View directory record Official record
Conditions
Hyperphosphatemia, End-stage Renal Disease
Interventions
ferric citrate
Drug
Lead sponsor
Keryx Biopharmaceuticals
Industry
Eligibility
19 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Sep 6, 2026, 8:15 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent Chronic Kidney Disease (CKD) Patients With Hyperphosphataemia

NCT02688764
View directory record Official record
Conditions
Hyperphosphatemia
Interventions
PA21 (Velphoro®), Calcium Acetate (Phoslyra®)
Drug
Lead sponsor
Vifor Fresenius Medical Care Renal Pharma
Industry
Eligibility
Up to 18 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
22
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Sep 6, 2026, 8:15 AM EDT
Completed Phase 4 Interventional Results available

A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP

NCT03988920
View directory record Official record
Conditions
Hyperphosphatemia, End Stage Renal Disease
Interventions
Tenapanor, Sevelamer Carbonate
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
Not listed
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Houston, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Sep 6, 2026, 8:15 AM EDT
Completed Phase 3 Interventional

Ferric Citrate for the Transition From CKD Stage 4/5 to CKD Stage 5D

NCT02492620
View directory record Official record
Conditions
Chronic Kidney Disease, Hyperphosphatemia, Iron Deficiency Anemia, Renal Insufficiency
Interventions
Ferric Citrate
Drug
Lead sponsor
Denver Nephrologists, P.C.
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Sep 6, 2026, 8:15 AM EDT
Completed Not applicable Interventional

Fosrenol and Phosphorus Balance - Lanthanum Carbonate

NCT01581996
View directory record Official record
Conditions
Chronic Kidney Failure, End-stage Renal Disease, Disorders Associated With Peritoneal Dialysis
Interventions
lanthanum carbonate
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
30 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Sep 6, 2026, 8:15 AM EDT
Completed Not applicable Interventional Results available

Low Phosphate Diets in Patients With Early Stages of Chronic Kidney Disease

NCT00438932
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Lanthanum Carbonate, Low Phosphorus Diet, Unrestricted Phosphorus Diet, Placebo
Drug · Dietary Supplement
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 26, 2011 · Synced Sep 6, 2026, 8:15 AM EDT
Completed Phase 1Phase 2 Interventional

A Clinical Study to Evaluate the Safety, Tolerability and Activity of a New Phosphate Binder (SBR759) in Patients With Chronic Kidney Disease on Hemodialysis

NCT00750295
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
SBR759
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 6, 2026, 8:15 AM EDT
Completed Not applicable Interventional Results available

Fibroblast Growth Factor-23 (FGF23) Reduction in Predialysis Chronic Kidney Disease (CKD)

NCT00843349
View directory record Official record
Conditions
Kidney Disease
Interventions
Lanthanum Carbonate, 900 mg Phosphate Diet, LC Placebo, Ad Libitum Diet
Drug · Other
Lead sponsor
Myles Wolf
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 6, 2013 · Synced Sep 6, 2026, 8:15 AM EDT
Completed Not applicable Interventional

Behavioral Management of Phosphorus in Hemodialysis Patients

NCT02940743
View directory record Official record
Conditions
Cardiovascular Disease (CKD), Hyperphosphatemia
Interventions
Education (Edu), SM intervention, Social Cognitive Therapy (SCT)
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
19 Years to 89 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Sep 6, 2026, 8:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Circadian Rhythm Modulation by Dietary Phosphorus in Chronic Kidney Disease

NCT01341678
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Lanthanum Carbonate, NeutraPhos, Diet Only
Drug · Dietary Supplement · Other
Lead sponsor
Geoffrey Block
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Sep 6, 2026, 8:15 AM EDT
Completed Not applicable Interventional Results available

Calcium and Phosphorus Balance and Calcium Kinetics in Patients With Stage 3/4 Chronic Kidney Disease

NCT01161407
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
1500 mg/d elemental calcium as calcium carbonate, Placebo
Dietary Supplement
Lead sponsor
Indiana University
Other
Eligibility
35 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 28, 2014 · Synced Sep 6, 2026, 8:15 AM EDT